Syngenta Seedcare launches PLENARIS™
- PLENARIS™ brings innovation to downy mildew control
- Adds new chemical mode of action for soil borne disease in sunflower and other crops
- Supported by best-in-class field expertise and the global Seedcare Institute network
- First sales in USA in 2017 followed by Argentina
PLENARIS™ contains oxathiapiprolin*, a novel chemistry with a new mode of action for control of fungal diseases caused by oomycetes. Downy mildew (Plasmopara halstedii) is the key seedling disease of sunflower causing severe stunting, discoloration of the leaves and reduction in root growth. Infected seedlings do not form a flowering head and consequently severely reducing yield.
Syngenta is the global leader in sunflower and with Seedcare portfolio innovations we are proud to support the efforts of breeders around the globe in their continuous fight against important seedling diseases and to help protect growers’ yields and investments in their crops.” Ioana Tudor, Syngenta Global Head of Seedcare
PLENARIS™ complements the leading Syngenta downy mildew control portfolio consisting of APRON XL®, DYNASTY® and BION® and will provide a unique ability to offer four different mode of actions to battle against this pathogen. Syngenta Seedcare products are supported by the Seedcare Institute network, consisting of best-in-class service hubs around the globe to offer our customers the best products and related support services.
PLENARIS™ will be first commercialized in the U.S. in 2017 followed by Argentina.
*Licensed from DuPont
Cautionary Statement Regarding Forward-Looking Statements
This news story contains forward-looking statements, which can be identified by terminology such as ‘expect’, ‘would’, ‘will’, ‘potential’, ‘plans’, ‘prospects’, ‘estimated’, ‘aiming’, ‘on track’ and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. We refer you to Syngenta's publicly available filings with the U.S. Securities and Exchange Commission for information about these and other risks and uncertainties. Syngenta assumes no obligation to update forward- looking statements to reflect actual results, changed assumptions or other factors. This document does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any ordinary shares in Syngenta AG, or Syngenta ADSs, nor shall it form the basis of, or be relied on in connection with, any contract therefore.